Browsing tag:

canagliflozin


On January 16, 2015 the Journal of Diabetes and its Complications shared positive findings from a recent post hoc analysis of Canagliflozin. Comprehensive data was analyzed from Phase 3 studies of Canagliflozin in adult patients with type 2 diabetes. This placebo-controlled study was comprised of four 26 week periods, with changes in HbA1c being sought[…]

Read More

The recent announcement from actor Tom Hanks revealing his diagnosis of Type 2 diabetes was stunning for Hollywood and his numerous fans. How could Tom, an in shape and active actor have this dreadful diagnosis? Endocrinologists believe a variety of factors contributed to Tom Hanks diabetes – particularly his type 2 status, including likely genetic components, weight[…]

Read More

Canagliflozin FDA approved as a new and unique treatment for type 2 diabetes. There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients. The recommended use for Canagliflozin patients includes a strict regimen of diet and exercise. The drug also outperforms similar[…]

Read More

An FDA Advisory Committee recommended the approval of Canagliflozin, CAS# 842133-18-0, for the treatment of type 2 diabetes. The approval in January 2013 was an encouraging move for Johnson and Johnson, who will market Canagliflozin as the brand Invokana. As an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service